|
|
Volumn 11, Issue 4, 2012, Pages 257-258
|
|
Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BMS 833923;
CYCLOPAMINE;
ERISMODEGIB;
ERIVEDGE;
LEQ 506;
NOTCH RECEPTOR;
PF 04449913;
PROTEIN GL1;
SARIDEGIB;
SMOOTHENED PROTEIN;
SONIC HEDGEHOG PROTEIN;
TAK 441;
TRANSCRIPTION FACTOR;
TUMOR MARKER;
UNCLASSIFIED DRUG;
VISMODEGIB;
WNT PROTEIN;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
BASAL CELL CARCINOMA;
BONE CANCER;
BRAIN CANCER;
CANCER CHEMOTHERAPY;
CANCER RESEARCH;
CANCER STEM CELL;
CANCER SURVIVAL;
CANCER SUSCEPTIBILITY;
CHRONIC MYELOID LEUKEMIA;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG POTENCY;
DRUG RESEARCH;
GENE ACTIVATION;
GENE MUTATION;
GENE OVEREXPRESSION;
HEAD AND NECK CARCINOMA;
HEDGEHOG GENE;
HUMAN;
INTRACELLULAR SIGNALING;
METASTASIS;
MOLECULARLY TARGETED THERAPY;
MYELOFIBROSIS;
NEOPLASM;
NONHUMAN;
ONCOGENE;
OVARY CANCER;
PANCREAS CANCER;
PATCHED 1 GENE;
PRIORITY JOURNAL;
PROTEIN SYNTHESIS INHIBITION;
RECURRENT CANCER;
SHORT SURVEY;
SMOOTHENED RECEPTOR GENE;
SQUAMOUS CELL CARCINOMA;
ANILIDES;
ANIMALS;
ANTINEOPLASTIC AGENTS;
HEDGEHOG PROTEINS;
HUMANS;
PYRIDINES;
SIGNAL TRANSDUCTION;
SKIN NEOPLASMS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84859321979
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3714 Document Type: Short Survey |
|
Times cited : (32)
|
|
References (0)
|
